Institutional Ownership
Transcode Therapeutics Inc
CUSIP 89357L501COM NEW 2025RNAZQ1 2026
13D / 13G Filings
5
Schedule 13D/13G on record
Beneficial Filers
3
Distinct reporting persons
Largest Stake
11.0%
Max % of class reported
Institutional Holders
6
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
5 filings · latest Jan 7, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Jan 7, 2026 | Sabby Management, LLC | 13G/A | 4.9% | 41.6K | SEC |
| 2 | Nov 10, 2025 | The Goldman Sachs Group, Inc. | 13G/A | 11.0% | 82 | SEC |
| 3 | Oct 28, 2025 | Ck Life Sciences Int'L., (Holdings) Inc. | 13D/A | 9.1% | — | SEC |
| 4 | Oct 16, 2025 | Ck Life Sciences Int'L., (Holdings) Inc. | 13D | 9.1% | — | SEC |
| 5 | Aug 14, 2025 | The Goldman Sachs Group, Inc. | 13G | 11.0% | 49.0K | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Geode Capital Management, LLC | 12.7K | $109.7K |
| 2 | Ubs Group AG | 8.3K | $71.4K |
| 3 | Tower Research Capital LLC (Trc) | 228 | $2.0K |
| 4 | Wells Fargo & Company/Mn | 55 | $474 |
| 5 | Sbi Securities Co., Ltd. | 12 | $103 |
| 6 | Royal Bank Of Canada | 8 | $0 |